The Investor Summit will showcase influential speakers who will express their views and offer invaluable insights on global investment opportunities. The conference offers a wonderful avenue for young companies and small-cap industries to get noticed by qualified investors, shareholders, and high-quality management teams.
For more information visit:
Conference Website
- Amesite Inc.
- ANEW MEDICAL INC.
- ARC Document Solutions, Inc.
- Artelo Biosciences, Inc.
- Atossa Therapeutics, Inc.
- Bazelet Health Systems, Inc.
- Blue Star Foods Corp.
- Data Storage Corporation
- Diamcor Mining Inc.
- Emmaus Life Sciences, Inc.
- Exagen Inc.
- Gaia, Inc.
- Global Crossing Airlines Group
- Healthy Extracts Inc.
- Hooker Furnishings Corporation
- HUMBL, Inc.
- Li-Metal Corp.
- LiveOne, Inc.
- Metro One Telecommunications Inc.
- Milestone Scientific Inc.
- Optimus Healthcare Services, Inc.
- Panacea Life Sciences Holdings, Inc.
- Pennexx Foods Inc.
- Plus Therapeutics, Inc.
- PolyPid Ltd.
- PyroGenesis Canada Inc.
- ReShape Lifesciences™
Amesite Inc. (NASDAQ: AMST)
Amesite Inc. (NASDAQ: AMST) an artificial intelligence driven platform and course designer, provides online products in the United States. The company uses machine learning to offer a mass customized experience to learners. Its customers include businesses, universities and colleges, K-12 schools, and non-profit organizations. The company was incorporated in 2017 and is headquartered in Detroit, Michigan. For more information, visit the company's website: amesite.com
ANEW MEDICAL INC.
ANEW MEDICAL, INC. is poised to disrupt the biopharma industry in a way that hasn't been seen in decades. Cell and gene therapies are the next wave of therapeutic innovation in the life sciences industry and the practice of medicine. ANEW is dedicated to realizing the potential of gene therapies to offer transformative patient outcomes in areas of high unmet medical need and extending the reach of gene therapies to highly prevalent neurodegenerative disorders like Alzheimer's and Parkinson's disease, and amyotrophic lateral sclerosis ("ALS" or "Lou Gehrig's disease"). They have assembled a portfolio of gene therapies in partnership with leading scientific institutions, and have built a core team with extensive experience in the gene therapy, drug development, and commercialization space. Their team pursues new innovations in gene-protein expression, vector design, and intracellular delivery to optimize their investigational cell and gene therapy products for safety, potency, durability, and immunologic response. They will continue to build in-house, integrated internal development capabilities from product development through commercialization and they will focus on ways to accelerate the pace of product development in the clinic. As part of their ongoing business strategy, they continue to explore potential opportunities to acquire or license new product candidates, as well as opportunities for partnership or collaboration on their existing products in development. Their vision is to build one of the world's leading cell and gene therapy company focused on the prevention and treatment of Alzheimer's Disease (AD) and other neurodegenerative diseases by progressing their current Klotho-based AD and ALS programs, and by identifying, developing and commercializing other novel gene therapy programs and treatments for devastating neurodegenerative diseases like Alzheimer's and Parkinson's. For more information, visit the company's website: www.anewmeds.com
ARC Document Solutions, Inc. (NYSE: ARC)
ARC Document Solutions, Inc. (NYSE: ARC) is a specialty digital print and services provider to business of all kinds, providing world-class service to more than 45,000 customers including some of the biggest brands in the world in design and construction, education, healthcare, marketing, manufacturing, technology, sports, and hospitality. For more information, visit the company's website: www.e-arc.com
Artelo Biosciences, Inc. (NASDAQ: ARTL)
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical executives collaborating with highly respected researchers and technology experts, Artelo applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. For more information, visit the company's website: artelobio.com
Atossa Therapeutics, Inc. (NASDAQ: ATOS)
Atossa Therapeutics, Inc. (NASDAQ: ATOS) a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. For more information, visit the company's website: www.atossatherapeutics.com
Bazelet Health Systems, Inc. (OTC: NBCO)
Neon Bloom, Inc. (OTC: NBCO), doing business as Bazelet Health Systems, Inc. ("Bazelet"), holds the exclusive license to grow in the United States a patented zero-THC, high CBG Cannabis sativa L plant, which received United States Patent No. PP32,725 on January 5, 2021. The patented plant, which was named PAN2020, is remarkably high in Cannabigerol (CBG) with undetectable levels (zero percent) of both Cannabidiol (CBD) and Tetrahydrocannabinol (THC). According to the published patent, PAN2020 produced 17% CBG, 0% CBD, 0% THC. The company's Cannabis-ZERO platform is actively developing non-GMO cannabis Sativa plants that produce zero-THC while being rich in CBG and other valuable cannabinoids. Bazelet is a wholly-owned subsidiary of the public company that produces and markets PECSA, a patent-pending, proprietary full extract of the PAN2020 plant with other added proprietary ingredients. PECSA stands for Plant-based EndoCannabinoid System Activator. The EndoCannabinoid System is the premier regulatory center of the body affecting mental abilities, emotions, pain, inflammation, immune and metabolic functions with receptors found primarily in the brain and immune cells. For more information, visit the company's website: bazelethealth.com
Blue Star Foods Corp. (NASDAQ: BSFC)
Blue Star Foods Corp. (NASDAQ: BSFC) is an integrated ESG seafood company that processes, packages and sells high-value seafood products. The Company believes it utilizes best-in-class technology, in both resource sustainability management and traceability, and ecological packaging. The Company also owns and operates the oldest continuously operating Recirculating Aquaculture System (RAS) full grow-out salmon farm in North America. For more information, visit the company's website: bluestarfoods.com
Data Storage Corporation (NASDAQ: DTST)
Data Storage Corporation (NASDAQ: DTST) delivers and supports a broad range of premium technology solutions from its six technical facilities throughout the USA and Canada focusing on cloud infrastructure, data storage and IT management. Clients look to Data Storage Corporation to ensure disaster recovery, business continuity, enhance cyber security, and meet increasing industry, state, and federal regulations. The Company markets to businesses, government, education, and the healthcare industry by leveraging its leading technologies in the creation of their solutions. Through its business units, the Company provides IaaS, SaaS, DRaaS, VoIP, cyber security, data analytics, IBM Power systems and storage hardware with managed IT services. For more information, visit the company's website: www.datastoragecorp.com
Diamcor Mining Inc. (OTCQB: DMIFF)
Diamcor Mining Inc. (OTCQB: DMIFF) has a proven history of supplying rough diamonds to the world market. The Company has established a long-term strategic alliance with world famous luxury retailer Tiffany & Co. and is now in the final stages of development, including, expanding processing volumes of the Krone-Endora Project, co-located with De Beers flagship Venetia diamond mine. Large scale trial mining is currently underway, with significant infrastructure, and a 30 year mining right now in place. Increasing demand for rough diamonds as supply becomes strained globally, presents a compelling opportunity for the Company. For more information, visit the company's website: www.diamcormining.com
Emmaus Life Sciences, Inc. (OTCQX: EMMA)
Emmaus Life Sciences, Inc. (OTCQX: EMMA) is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets U.S. Food and Drug Administration approved Endari® (L-glutamine oral powder) indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as diverticulosis. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California. For more information, visit the company's website: www.emmausmedical.com
Exagen Inc. (NASDAQ: XGN)
Exagen Inc. (NASDAQ: XGN) is a Patient Focused, Discovery Driven company with a growing menu of proprietary tests focusing in the area of Rheumatology and Autoimmune diseases. Their AVISE testing portfolio is specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. For more information, visit the company's website: exagen.com
Gaia, Inc. (NASDAQ: GAIA)
Gaia, Inc. (NASDAQ: GAIA) operates a digital video subscription service and on-line community for underserved member base in the United States, Canada, Australia, and internationally. It has a digital content library of approximately 10,000 titles in Spanish, German, and French languages available to its subscribers on internet-connected devices. The company's network includes Yoga channel, which provides access to yoga, eastern arts, and other movement based classes; Transformation channel that offers spiritual growth, personal development, and consciousness content; Alternative Healing channel, which features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity; and Seeking Truth channel that offers category-leading talent that enables to draw speakers, authors, and experts in the alternative media world. It also operates gaia.com and gaiamtv.com websites. Gaia, Inc. complements its produced and owned content through long term licensing agreements. The company was formerly known as Gaiam, Inc. and changed its name to Gaia, Inc. in July 2016. Gaia, Inc. was incorporated in 1988 and is headquartered in Louisville, Colorado. For more information, visit the company's website: www.gaia.com
Global Crossing Airlines Group (OTCQB: JETMF)
Global Crossing Airlines Group (OTCQB: JETMF) is a US 121 domestic flag and supplemental airline flying the Airbus A320 family aircraft. GlobalX flies as a passenger ACMI and charter airline serving the US, Caribbean, and Latin American markets. In 2022, GlobalX will enter ACMI cargo service flying the A321 freighter, subject to DOT and FAA approvals. For more information, visit the company's website: www.globalairlinesgroup.com
Healthy Extracts Inc. (OTCQB: HYEX)
Healthy Extracts Inc. (OTCQB: HYEX) is a platform for developing or acquiring science-forward, clinically proven, plant-based proprietary products in select high-growth categories within the fast-growing multibillion-dollar nutraceutical market. Two of which they have acquired in the heart and brain health sectors (Bergamet North America and Ultimate Brain Nutrients).For more information, visit the company's website: healthyextractsinc.com
Hooker Furnishings Corporation (NASDAQ: HOFT)
Hooker Furnishings Corporation (NASDAQ: HOFT), in its 98th year of business, is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture and fabric-upholstered furniture for the residential, hospitality and contract markets. The Company also domestically manufactures premium residential custom leather and custom fabric-upholstered furniture. It is ranked among the nation's largest publicly traded furniture sources, based on 2020 shipments to U.S. retailers, according to a 2021 survey by a leading trade publication. Major casegoods product categories include home entertainment, home office, accent, dining, and bedroom furniture in the upper-medium price points sold under the Hooker Furniture brand. Hooker's residential upholstered seating product lines include Bradington-Young, a specialist in upscale motion and stationary leather furniture, Sam Moore Furniture, a specialist in upscale occasional chairs, settees, sofas and sectional seating with an emphasis on cover-to-frame customization, Hooker Upholstery, imported upholstered furniture targeted at the upper-medium price-range and Shenandoah Furniture, an upscale upholstered furniture company specializing in private label sectionals, modulars, sofas, chairs, ottomans, benches, beds and dining chairs in the upper-medium price points for lifestyle specialty retailers. The H Contract product line supplies upholstered seating and casegoods to upscale senior living facilities. The Home Meridian division addresses more moderate price points and channels of distribution not currently served by other Hooker Furnishings divisions or brands. Home Meridian's brands include Accentrics Home, home furnishings centered around an eclectic mix of unique pieces and materials that offer a fresh take on home fashion, Pulaski Furniture, casegoods covering the complete design spectrum in a wide range of bedroom, dining room, accent and display cabinets at medium price points, Samuel Lawrence Furniture, value-conscious offerings in bedroom, dining room, home office and youth furnishings, Prime Resources, value-conscious imported leather upholstered furniture, and Samuel Lawrence Hospitality, a designer and supplier of hotel furnishings. The Sunset West division is a designer and manufacturer of comfortable, stylish and high-quality outdoor furniture. Hooker Furnishings Corporation's corporate offices and upholstery manufacturing facilities are located in Virginia and North Carolina, with showrooms in High Point, N.C., Las Vegas, N.V. and Ho Chi Minh City, Vietnam. The company operates distribution centers in North Carolina, Virginia, Georgia, California, China and Vietnam. For more information, visit the company's website: www.hookerfurnishings.com
HUMBL, Inc. (OTCQB: HMBL)
HUMBL, Inc. (OTCQB: HMBL) is a Web3 blockchain company. Key HUMBL products and services include: (a) a mobile wallet to buy, sell and send cryptocurrencies and make payments; (b) an NFT gallery and authentication service; (c) a blockchain services division for development of government and commercial blockchain applications; (d) a suite of cryptocurrency index and thematic trading products; and (e) primary and secondary ticketing platforms. HUMBL is based in San Diego, California. For more information, visit the company's website: www.humbl.com
Li-Metal Corp. (CSE: LIM) (OTC Pink: LIMFF)
Li-Metal Corp. (CSE: LIM) (OTC Pink: LIMFF) engages in developing lithium metal anodes and lithium metal production technologies for use in next generation batteries. The company is based in Markham, Canada. For more information, visit the company's website: www.li-metal.com
LiveOne, Inc. (NASDAQ: LVO)
LiveOne, Inc. (NASDAQ: LVO) is a creator-first, music, entertainment and technology platform focused on delivering premium experiences and content worldwide through memberships and live and virtual events. As of April 1, 2022, the Company has accrued a paid and free membership base of over 2.23 million**, streamed over 2,900 artists, has a library of 30 million songs, 600 curated radio stations, nearly 270 podcasts/vodcasts, hundreds of pay-per-views, personalized merchandise, released music-related NFTs, and created a valuable connection between fans, brands, and bands. The Company's wholly-owned subsidiaries include Slacker Radio, React Presents, Gramophone Media, Palm Beach Records, Custom Personalization Solutions, LiveXLive, PPVOne and PodcastOne, which generates more than 2.48 billion downloads per year and 300+ episodes distributed per week across its stable of top-rated podcasts. LiveOne is available on iOS, Android, Roku, Apple TV, Amazon Fire, and through OTT, STIRR, and XUMO. For more information, visit the company's website: www.liveone.com
Metro One Telecommunications Inc. (OTC Pink: WOWI)
Metro One Telecommunications Inc. (OTC Pink: WOWI) is changing the way retailers integrate mobile commerce solutions within their businesses. The company's unique ability to merge mobile technology and patented user interfaces enables retailers to quickly and easily put their businesses online and, significantly increase customer retention, basket size and lifetime value. Metro one is the holding company of Stratford Ltd (www.shelfy.io) a next-gen, instant mobile commerce platform enhanced with a proprietary digital advertising media suite tool. The platform enables online and offline retailers to rapidly leverage existing customer data for an interactive shopping experience – without coding. Shelfy's mobile commerce product suite includes an mCommerce Platform, mCommerce Enterprise Platform, Digital Media Suite and fully comprehensive Instore Engagement Suite. Shelfy empowers businesses to grow their customer retention, engagement, and their revenues, with minimum hassle. For more information, visit the company's website: metro1telecomm.com
Milestone Scientific Inc. (NYSE: MLSS)
Milestone Scientific Inc. (NYSE: MLSS) a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. For more information, visit the company's website: www.milestonescientific.com
Optimus Healthcare Services, Inc. (OTC Pink: OHCS)
Optimus Healthcare Services, Inc. (OTC Pink: OHCS) is focused on creating a network of innovative healthcare companies that advance clinical research, disease management and improve physician/patient interactions. Optimus Healthcare accomplishes this by acquiring controlling interest in a variety of healthcare-related businesses and then enhances the attributes of its portfolio companies by improving the operational, technological and managerial capabilities of each company. Optimus Healthcare's portfolio of companies includes, Telehealth and Compliance Technology (TACT) companies, PainScript and HealthScript, the Clinical Research Alliance (CRA), a research services provider focused on bringing state-of-the-art clinical trial capabilities to community-based physicians and their patients, and VaccinationsRx, a boutique concierge vaccination pharmacy dedicated to simplifying access to vaccines. For more information, visit the company's website: www.optimushealthcare.com
Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH)
Panacea Life Sciences Holdings, Inc. (OTCQB: PLSH) is a seed-to-sale cannabinoid and nutraceutical manufacturer and research company that produces purposeful, natural pharmaceutical alternatives for consumers and pets. Theymanufacture and sell softgels, gummies, tinctures, sublingual tablets, patches, K-Tape, cosmetics, skin care and other topicals. Panacea was founded by Leslie Buttorff in 2017 as a woman-owned business. Panacea was formed to own and engage in creating disruptive healthcare and veterinary solutions with a specific focus on hemp. Their goals are to research, produce, and distribute products both domestically and internationally that target and treat major categories of medical conditions: pain, cancer, psychological, epilepsy, gastrointestinal, autoimmune, neurological, and sleep disorders. These categories include conditions that affect hundreds of millions of patients and animals worldwide. Their vision is to become the leading research and manufacturing cannabinoid and nutraceutical company (top 10 in terms of revenue and brand) in the U.S. and globally with a research arm focused on pre-clinical research in order to develop purposeful solutions for their human and animal customers. For more information, visit the company's website: panacealife.com
Pennexx Foods Inc. (OTC Pink: PNNX)
Pennexx Foods Inc. (OTC Pink: PNNX) is a technology company within the Software / Internet and Fintech industries through its wholly owned subsidiaries. Pennexx's products capitalize on the multibillion dollar social media market by enabling merchants to use social media to acquire, retain and grow their customer base. YSO users scan a QR code or click a post online, register and share that reward with their friends. Pennexx is developing prepaid debit cards which link to its YSO program so rewards can be automatically added. YSO will also leverage artificial intelligence to optimize and create targeted marketing campaigns. Pennexx is creating a unique pre-paid debit card. Pennexx utilizes patent pending technology. Pennexx earns money through subscription fees, per use charges, transactional fees and contracts with its customers. Pennexx is poised to reach millions of users through its viral social media approach. Pennexx helps businesses grow more efficiently than traditional marketing campaigns. It is as powerful as word of mouth advertising. This approach decreases the acquisition cost of acquiring new customers. Customers login through the merchant portal to control their campaigns and view reports on the status of their success. YSO has shown a 96% adoption rate among businesses it approaches, making the program a very exciting opportunity for rapid growth. For more information, visit the company's website: pennexx.net
Plus Therapeutics, Inc. (NASDAQ: PSTV)
Plus Therapeutics, Inc. (NASDAQ: PSTV) a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Its proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. For more information, visit the company's website: plustherapeutics.com
PolyPid Ltd. (NASDAQ: PYPD)
PolyPid Ltd. (NASDAQ: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For more information, visit the company's website: www.polypid.com
PyroGenesis Canada Inc. (NASDAQ: PYR)
PyroGenesis Canada Inc. (NASDAQ: PYR) a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and sustainable solutions which reduce greenhouse gases (GHG), and are economically attractive alternatives to conventional "dirty" processes. PyroGenesis has created proprietary, patented and advanced plasma technologies that are being vetted and adopted by multiple multibillion dollar industry leaders in four massive markets: iron ore pelletization, aluminum, waste management, and additive manufacturing. With a team of experienced engineers, scientists and technicians working out of its Montreal office, and its 3,800 m2 and 2,940 m2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The operations are ISO 9001:2015 and AS9100D certified, having been ISO certified since 1997. For more information, visit the company's website: www.pyrogenesis.com
ReShape Lifesciences™ (NASDAQ: RSLS)
ReShape Lifesciences™ (NASDAQ: RSLS) is America's premier physician-led weight loss and metabolic health solutions company, offering an integrated portfolio of proven products and services including the FDA-approved, insurance-reimbursed, next-generation Lap-Band® program. The Lap-Band program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. It also offers reshapecare™ virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. For more information, visit the company's website: www.reshapelifesciences.com/
Sachem Capital Corp. (NYSE American: SACH)
Sachem Capital Corp. (NYSE American: SACH) is a Connecticut-based real estate finance company that specializes in originating, servicing and managing a portfolio of first mortgage loans. It offers short-term (i.e., three years or less) secured, non¬banking loans (sometimes referred to as "hard money" loans) to real estate investors to fund their acquisition, renovation, development, rehabilitation or improvement of properties located primarily in Connecticut. The company does not lend to owner occupants. The company's primary underwriting criteria is a conservative loan to value ratio. The properties securing the company's loans are generally classified as residential or commercial real estate and, typically, are held for resale or investment. Each loan is secured by a first mortgage lien on real estate. Each loan is also personally guaranteed by the principal(s) of the borrower, which guaranty may be collaterally secured by a pledge of the guarantor's interest in the borrower. The company also makes opportunistic real estate purchases apart from its lending activities. The company believes that it qualifies as a real estate investment trust (REIT) for federal income tax purposes and has elected to be taxed as a REIT beginning with its 2017 tax year. For more information, visit the company's website: www.sachemcapitalcorp.com
SG Blocks, Inc. (NASDAQ: SGBX)
SG Blocks, Inc. (NASDAQ: SGBX) is a leading developer, designer, and fabricator of modular structures, meeting the growing demand for safe and green construction. The firm offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders and owners in achieving faster execution, greener construction, and buildings of higher value. The Company creates purpose built, pre-fabricated modules from wood, steel, and shipping containers into supreme structures. For more information, visit the company's website: www.sgblocks.com
Sky Technologies (NASDAQ: SKYX)
Sky Technologies (NASDAQ: SKYX) has a series of highly disruptive advanced-safe-smart platform technologies, with over 60 U.S. and global patents and patent pending applications. Their technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. Theybelieve that their products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, visit the company's website: skyplug.com
Sono-Tek Corporation (NASDAQ: SOTK)
Sono-Tek Corporation (NASDAQ: SOTK) is the leading developer and manufacturer of ultrasonic coating systems for applying precise, thin film coatings to protect, strengthen or smooth surfaces on parts and components for the microelectronics/electronics, alternative energy, medical and industrial markets, including specialized glass applications in construction and automotive. The Company's solutions are environmentally friendly, efficient and highly reliable, and enable dramatic reductions in overspray, savings in raw material, water and energy usage and provide improved process repeatability, transfer efficiency, high uniformity and reduced emissions. For more information, visit the company's website: www.sono-tek.com
Spectral Medical Inc. (TSX: EDT)
Spectral Medical Inc. (TSX: EDT) is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy ("RRT") across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market. Dialco is currently pursuing regulatory approval for U.S. in-home use of DIMI, which is based on the same RRT platform as SAMI, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings, and obtained its Health Canada license for use within Canadian hospitals, clinics and in home. For more information, visit the company's website: spectraldx.com
Stran & Company (NASDAQ: STRN)
Stran & Company (NASDAQ: STRN) has grown to become a leader in the promotional products industry, specializing in complex marketing programs to help recognize the value of promotional products, branded merchandise, and loyalty incentive programs as a tool to drive awareness, build brands and impact sales. Stran is the chosen partner of many Fortune 500 companies, across a variety of industries, to execute their promotional marketing, loyalty and incentive, sponsorship activation, recruitment, retention, and wellness campaigns. Stran provides world-class customer service and utilizes cutting-edge technology, including efficient ordering and logistics technology to provide order processing, warehousing, and fulfillment functions. The Company's mission is to develop long-term relationships with its clients, enabling them to connect with both their customers and employees in order to build lasting brand loyalty. For more information, visit the company's website: www.stran.com
Taal Distributed Information Technologies Inc. (CSE: TAAL)
Taal Distributed Information Technologies Inc. (CSE: TAAL) through its subsidiaries, provides blockchain infrastructure and transactional platforms to support businesses building solutions and applications in Canada and Cayman Island. It also engages in the developing, operating, and managing distributed computing systems for enterprise users. The company was formerly known as Squire Mining Ltd. and changed its name to Taal Distributed Information Technologies Inc. in December 2019. Taal Distributed Information Technologies Inc. was incorporated in 2011 and is based in Toronto, Canada. For more information, visit the company's website: www.taal.com
Todos Medical Ltd. (OTCQB: TOMDF)
Todos Medical Ltd. (OTCQB: TOMDF) a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel. For more information, visit the company's website: todosmedical.com
Tonix Pharmaceuticals (NASDAQ: TNXP)
Tonix Pharmaceuticals (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-15001 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix's rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix's infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix's lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix's recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v.solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company's CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. For more information, visit the company's website: www.TonixPharma.com
Tower One Wireless Corp. (OTCQB: TOWTF)
Tower One Wireless Corp. (OTCQB: TOWTF) owns, develops, and operates build-to-suit multitenant communications structures in Canada, Colombia, Mexico, the United States, and Ecuador. Tower One Wireless focuses primarily on the construction of towers in municipalities where cellular coverage is limited or non-existent, and engages in the leasing of space on communications sites to mobile network operators. The company also provides tower-related services, including site acquisition, zoning and permitting, structural analysis, and construction. Tower One Wireless Corp. was founded in 2015 and is based in Vancouver, Canada. For more information, visit the company's website: toweronewireless.com
Trust Stamp Inc. (NASDAQ: IDAI)
Trust Stamp Inc. (NASDAQ: IDAI) is a global provider of AI-powered identity services for use in multiple sectors including banking and finance, regulatory compliance, government, real estate, communications, and humanitarian services. Its technology empowers organizations with advanced biometric identity solutions that reduce fraud, protect personal data privacy, increase operational efficiency, and reach a broader base of users worldwide through its unique data transformation and comparison capabilities. For more information, visit the company's website: truststamp.ai
Universal Media Group Inc. (OTC Pink: UMGP)
Universal Media Group Inc. (OTC Pink: UMGP) is a leading producer and distributor of both short and long form content, covering a diverse array of genres, for multiple media platforms. UMGP also focuses on the implementation of celebrity based programming through social media and streaming video on demand platforms. Through programming created under the UMGP banner, coupled with targeted program acquisitions, and aggressive national marketing campaigns, UMGP is focused on multiple new revenue verticals while continuing to develop its multiple in-house projects. UMGP is actively broadening its sales channels, both domestically and internationally, of its already existing content library and new products. UMGP is also focused on 4K programming with projects centered in social media, television, motion pictures, and the NFT space for celebrity centric NFT creation and sales. UMGP will continue to pursue strategic business investments, partnerships and acquisitions that will ultimately increase profitability and expand the company's reach, focus, and portfolio of business assets. For more information, visit the company's website: www.umediagroupinc.com
Ur-Energy Inc. (NYSE American: URG)
Ur-Energy Inc. (NYSE American: URG) owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming. In 2021, Lost Creek received an amendment to its license allowing expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project. The license now allows annual plant production up to 2.2 million pounds U3O8, which includes wellfield production of up to 1.2 million pounds U3O8 and toll processing of up to one million pounds U3O8. Additional approvals for this expansion are expected in 2022. Their second uranium in situ recovery facility, Shirley Basin Project, has received all major authorizations and is construction ready. Ur-Energy engages in the identification, acquisition, exploration, development, and operation of uranium projects. For more information, visit the company's website: www.ur-energy.com